Premium
Engineered CaS clusters to limit breast cancer cell growth and proliferation selectively
Author(s) -
Castro Miguel,
Suarez Edu,
Rivera Daniel,
Adorno Wilmer,
Munoz Kevin
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.565.6
Subject(s) - cancer cell , cell growth , apoptosis , cell , cell cycle , chemistry , fibroblast , nanoclusters , in vitro , cancer , intracellular , in vivo , cancer research , biology , medicine , biochemistry , microbiology and biotechnology , organic chemistry
The pH is a major difference between normal and cancer cells. Thermodynamic calculations indicate that CaS has limited dissociation in slightly basic pH, like the one found in normal cells, but dissociates easily into H 2 S and Ca 2+ in the acidic pH found in cancer cell environments. We have studied the effect of CaS – in the size range of a few A to about 1 nm‐ in the cell cycle of breast cancer and normal fibroblasts. A single dose of CaS nanoclusters does not affect the survival and growth rate of normal fibroblasts but inhibits the proliferation rate of carcinoma cells in vitro . Human carcinoma cells treated with the CaS nanocluster dispersion exhibited a decreased ability to properly enter the cell cycle marked by a decrease in cell concentration in G0/G1 phase at 24‐ hours post treatment and then an increase in cells held in the SubG1 and G0/G1 phases up to 72‐hours post treatment. Apoptosis and necrotic channels were found to play significant roles in the death of human carcinoma exposed to the CaS nanoclusters. In contrast, any effect on normal fibroblasts appeared to be short lived and non‐detrimental. Passive uptake and intracellular pH levels of carcinoma cells are proposed to result in the observed selectivity of CaS to inhibit cancer cell proliferation with no significant effect on normal fibroblast cells. The results encourage further research with other cell lines in vitro as well as in vivo to translate this nanotechnology into clinical use. Support or Funding Information NIH RISE #R25GM096955NIH RISE 5R25GM088023‐02 This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .